Katie Heller, Author at ECOG-ACRIN Advocacy Blog

Filter by
Categories
Tags
Authors
Show all

All
Editorials
New Trials
Ongoing Trials
Trial Results

All
Acute lymphoblastic leukemia
Acute myeloid leukemia
Adolescents and young adults
Advocacy
Anal cancer
Antioxidants
AYA
Bladder cancer
Blood cancers
Breast cancer
Cancer care delivery
Caregiving
Chemotherapy
Chronic lymphocytic leukemia
Colorectal cancer
ComboMATCH
Communication
COVID-19
DCIS
De-escalation
Esophagus cancer
Financial hardship
Gallbladder cancer
Gastroesophageal cancer
GI cancer
Green tea
HAI chemotherapy
Head and neck cancer
Health equity
Hepatic arterial infusion chemotherapy.
HER2+ breast cancer
Hormone therapy
Imaging
Immune system therapy
Immunotherapy
Implementation science
In memory
Kidney cancer
Language
Late Effects
Leukemia
LGBTQ+
Liver cancer
Lung cancer
Lymphoma
Mammography
Mantle cell lymphoma
Melanoma
Men's health
Mesothelioma
Minimal residual disease
MRI
Multiple myeloma
Myelodysplastic syndrome
Myeloma
National Clinical Trials Network
NCI-MATCH
Neuropathy
Nose and sinus cancer
Older adults
Pancreatic cancer
Pancreatic cysts
Patient care
Patient education
Patient navigation
Patient-reported outcomes
Penile cancer
Personalized medicine
Personalized screening
Personalized treatment
Precision medicine
Prevention
Prostate cancer
Radiation therapy
Rare cancer
Renal cell carcinoma
Research results
Sarcoma
Screening
Sexual and gender minorities
Side effects
Skin cancer
Smoldering multiple myeloma
Social genomics
Soft tissue sarcoma
Solid tumors
Squamous cell carcinoma
Surveillance
Survivorship
Symptom management
Symptom science
Targeted therapy
Throat cancer
Triple-negative breast cancer
Tumor test
Upper tract urothelial cancer
Urothelial cancer

All
Diane Dragaud
ECOG-ACRIN Staff
Katie Heller

January 5, 2023

January 5, 2023

Categories

Ongoing Trials

Ongoing Trial: The INSIGNA clinical trial is testing the timing of immunotherapy alone or with chemotherapy for patients with advanced lung cancer

This trial is seeking to find out whether patients with the PD-L1 biomarker can either delay having chemotherapy or avoid it altogether

September 26, 2022

Categories

Editorials

For people with stage 4 cancer, survivorship is complicated

Robin Evans, a research advocate with the ECOG-ACRIN Cancer Research Group, shares her perspective on navigating the survivorship community as someone living with stage 4 cancer

December 15, 2021

December 15, 2021

Categories

Trial Results

Trial Results: Blood cancers are the focus of recent ECOG-ACRIN research

Summaries of leukemia, lymphoma, and myeloma research results

September 20, 2021

September 20, 2021

Categories

Editorials

The language of (lung) cancer

A new language guide encourages respect, eliminates blame, and promotes health equity